Latest research on Welchol

Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.

Latest findings

Of these, 105 (62.1 %) used statin monotherapy and another 63 subjects (37.3 %) used statins in combination with other lipid-lowering drugs, either Ezetimibe (n = 61) or CholestaGel (n = 2). [source, 2015]
One subject received CholestaGel monotherapy. [source, 2015]
Five of 11 (45.5%) patients were on a nonstatin cholesterol lowering medications, including 1 (9.1%) on colesevelam (Welchol), 3 (27.3%) on ezetimibe (Zetia), and 1 (9.1%) on Niacin. [source, 2014]
The study was repeated in DIO mice treated with FGFR4 ASO #1 at 50 mg/kg /week and fed the 58% HF diet mixed with 2% Welchol, a bile acid sequestrant; the latter was used to eliminate FGFR4 reduction caused increase in plasma FGF15 levels. [source, 2013]
To further determine whether the increased FGF15 level is an underlying mediator, DIO mice treated with or without FGFR4 ASO plus Welchol were infused continually with recombinant, biologically active FGF19 at a dose of 100 ng/kg/day for 7 days. [source, 2013]
Welchol feeding not only reduced the plasma FGF15 levels in the mice without FGFR4 ASO treatment, but also suppressed the plasma FGF15 levels in FGFR4 ASO-treated mice to the levels of mice without FGFR4 ASO treatment (Figure 7A). [source, 2013]
FGF19, but not saline, caused significant increases in VO2 (Figure 7D) and whole body heat production as well (Figure 7E) during infusion in the mice without FGFR4 ASO treatment or with FGFR4 ASO treatment plus Welchol feeding. [source, 2013]
In late 2000, colesevelam HCL (Welchol) was approved by the U.S. [source, 2013]
The study was funded by Daiichi-Sankyo, Inc (DSI), the makers of colesevelam HCL (Welchol). [source, 2013]
The GLOWS (Glucose-Lowering Effect of Welchol) study was a prospective, double-blind, placebo-controlled, parallel design, add-on trial in which 65 less than optimally controlled type 2 DM patients (mean HbA1c 7.9%; mean fasting blood sugar [FBS] 170 mg/dL; mean 1-hour postprandial glucose 269 mg/dL), being treated with sulfonylurea and/or Metformin, were randomized to receive either colesevelam 3.8 g/day or placebo. [source, 2012]